<?xml version = '1.0' encoding = 'UTF-8'?>
<?xml-stylesheet href="/rss/styledrssBMC.css" type="text/css"?>
<rdf:RDF xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns="http://purl.org/rss/1.0/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:extra="http://www.biomedcentral.com/xml/schemas/extra/" xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/" xmlns:cc="http://web.resource.org/cc/">
	<channel rdf:about="http://www.biomedcentral.com/rss">
		<extra:info rdf:parseType="Literal">
			<html:div xmlns:html="http://www.w3.org/1999/xhtml" style="font:14px Verdana, Geneva, Arial, Helvetica, sans-serif">
				<html:span style="font-weight:bold">This is an RSS newsfeed from BioMed Central</html:span>
				<html:br/>
				<html:span style="font-size: 12px;">It is intended to be used with an RSS reader. For more information about RSS newsfeeds from BioMed Central, visit <html:br/><html:a href="http://www.biomedcentral.com/info/about/rss/" style="color:#3333CC; font-size:12px;">http://www.biomedcentral.com/info/about/rss/</html:a><html:br/>
				</html:span>
			</html:div>
		</extra:info>
		<title>Diagnostic Pathology - Latest articles</title>
		<link>http://www.diagnosticpathology.org</link>
		<description>The latest articles from Diagnostic Pathology (ISSN 1746-1596) published by 
				
				BioMed Central
		</description>
        <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        <items>
            <rdf:Seq>
            
				    <rdf:li rdf:resource="http://www.diagnosticpathology.org/content/3/1/35"/>			    
            
				    <rdf:li rdf:resource="http://www.diagnosticpathology.org/content/3/1/34"/>			    
            
				    <rdf:li rdf:resource="http://www.diagnosticpathology.org/content/3/1/33"/>			    
            
				    <rdf:li rdf:resource="http://www.diagnosticpathology.org/content/3/1/32"/>			    
            
				    <rdf:li rdf:resource="http://www.diagnosticpathology.org/content/3/1/31"/>			    
            
				    <rdf:li rdf:resource="http://www.diagnosticpathology.org/content/3/1/30"/>			    
            
				    <rdf:li rdf:resource="http://www.diagnosticpathology.org/content/3/1/29"/>			    
            
				    <rdf:li rdf:resource="http://www.diagnosticpathology.org/content/3/1/28"/>			    
            
				    <rdf:li rdf:resource="http://www.diagnosticpathology.org/content/3/1/27"/>			    
            
				    <rdf:li rdf:resource="http://www.diagnosticpathology.org/content/3/1/26"/>			    
            
            </rdf:Seq>
        </items>
    </channel>  
    
		<item rdf:about="http://www.diagnosticpathology.org/content/3/1/35">
            
            <title>TKTL1 is overexpressed in a large portion of non small cell lung cancer specimens</title>
			<description>In several tumors the transketolase activity, controlled inter alia by enzymes of the pentose phosphate pathway which is an alternative, energy generating reaction-cascade to glycolysis, has been correlated with proliferation. The increase of thiamine-dependant transketolase enzyme reactions is induced especially through upregulated transketolase-like enzyme 1 (TKTL1)-activity; that shows TKTL1 to be a causative enzyme for tumors enhanced, anaerobic glucose degradation. We investigated TKTL1-expression in 88 human, formalin-fixed non small cell lung cancer tissues and 24 carcinomas of the breast by immunohistochemical stainings applying a 0 to 3 staining-score system (3 = strongest expression). For means of validation we additionally stained a 40 NSCLC fixed and paraffin-embedded utilizing the HOPE-technique; showing comparable results to the formalin-fixed, paraffin-embedded specimens (not shown). Potential correlations with age, sex, TNM-classification parameters and tumor grading as well as tumor transcription factor 1 (TTF1) and surfactant protein A (SPA) expression were investigated. 40.9% of the analyzed lung tumors expressed TKTL1 weakly (Score 1), 38.6% moderately (score 2) and 17.1% strongly (score 3). 3 tumors were diagnosed TKTL1-negative (3.4%; score 0). All Breast cancer specimen stainings were positive and scored 1: 32%; scored 2: 36%; scored 3: 32%. Alveolar macrophages and Alveolar Epithelial Cells Type II were also found to be TKTL1-positive. 
None of the listed clinical parameters could be found to show a significant correlation to TKTL1 signal appearance.
Although we describe the expression of TKTL1 in lung cancers, we need to state that up till now there is no scientific indication for any treatment regimens based upon these findings.</description>
			<link>http://www.diagnosticpathology.org/content/3/1/35</link>
			
			 	<dc:creator>Holger Schultz, Daniel Kahler, Detlev Branscheid, Ekkehard Vollmer, Peter Zabel and Torsten Goldmann</dc:creator>
			
			<dc:source>Diagnostic Pathology 2008, 3:35</dc:source>
			<dc:date>2008-08-12</dc:date>
			<dc:identifier>doi:10.1186/1746-1596-3-35</dc:identifier>
			
			
							
					<prism:publicationName>Diagnostic Pathology</prism:publicationName>
					
			
							
					<prism:issn>1746-1596</prism:issn>
					
			
							
					<prism:volume>3</prism:volume>
					
			
							
					<prism:startingPage>35</prism:startingPage>
					
			
							
					<prism:publicationDate>2008-08-12</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://www.diagnosticpathology.org/content/3/1/34">
            
            <title>Atypical adenomatous hyperplasia (adenosis) of the prostate: A case report with review of the literature</title>
			<description>A 62-year-old male presented with symptoms of urinary obstruction and elevated serum prostate-specific antigen level of 3.61 ng/mL. Prostate needle biopsies showed benign prostatic tissue with a focus of crowded glands with minimal cytological atypia, fairly well-circumscribed with infiltrative appearance of glands at the edges. This focus had both small and larger glands with similar histological features. This focus was strongly positive for alpha-methylacyl-coenzyme A-racemase (AMACR), but showed scattered patchy staining with basal cell markers (p63 and CK903/34betaE12). Hence, the final histologic diagnosis was benign prostatic tissue with a focus of florid adenosis. Two subsequent follow-up prostate needle biopsies performed six and 12 months later both showed benign prostatic tissue with atrophic changes. This case highlights the utility of these three immunostains (AMACR, p63 and CK903/34betaE12) in the accurate diagnosis of adenosis of the prostate on needle biopsy, and avoiding its misinterpretation as prostate adenocarcinoma.</description>
			<link>http://www.diagnosticpathology.org/content/3/1/34</link>
			
			 	<dc:creator>Henry B Armah and Anil V Parwani</dc:creator>
			
			<dc:source>Diagnostic Pathology 2008, 3:34</dc:source>
			<dc:date>2008-08-12</dc:date>
			<dc:identifier>doi:10.1186/1746-1596-3-34</dc:identifier>
			
			
							
					<prism:publicationName>Diagnostic Pathology</prism:publicationName>
					
			
							
					<prism:issn>1746-1596</prism:issn>
					
			
							
					<prism:volume>3</prism:volume>
					
			
							
					<prism:startingPage>34</prism:startingPage>
					
			
							
					<prism:publicationDate>2008-08-12</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://www.diagnosticpathology.org/content/3/1/33">
            
            <title>A diagnostic dilemma in breast pathology - benign fibroadenoma with 
multinucleated stromal giant cells</title>
			<description>Fibroadenomas are common benign breast tumours that display a characteristic pathological morphology, although several epithelial and stromal variations exist. A very rare histological finding is the presence of multinucleated giant cells throughout the stroma of a benign fibroadenoma. Cells of this type, which are more commonly found incidentally within the interlobular stroma of breast tissue, are benign and should not be mistaken for malignant cells on microscopic examination. Unfortunately a lack of awareness of this pathological entity can lead to diagnostic confusion amongst pathologists resulting in the multinucleate giant cells being mistaken for highly mitotic cells and consequently the fibroadenoma being mistaken for a malignant lesion. This may have serious implications for the subsequent management of the patient. The presence of this unusual cell type in the stroma does not alter the prognosis of otherwise benign lesion. We encountered two such cases at our institution in a six month period recently. We present their histories along with relevant radiological, microscopic and immunohistochemical features, followed by a discussion of this unusual pathological entity.</description>
			<link>http://www.diagnosticpathology.org/content/3/1/33</link>
			
			 	<dc:creator>Helen M Heneghan, Sean T Martin, Mary Casey, Igdam Tobbia, Fadel Benani and Kevin M Barry</dc:creator>
			
			<dc:source>Diagnostic Pathology 2008, 3:33</dc:source>
			<dc:date>2008-08-01</dc:date>
			<dc:identifier>doi:10.1186/1746-1596-3-33</dc:identifier>
			
			
							
					<prism:publicationName>Diagnostic Pathology</prism:publicationName>
					
			
							
					<prism:issn>1746-1596</prism:issn>
					
			
							
					<prism:volume>3</prism:volume>
					
			
							
					<prism:startingPage>33</prism:startingPage>
					
			
							
					<prism:publicationDate>2008-08-01</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://www.diagnosticpathology.org/content/3/1/32">
            
            <title>mtDNA sequence variants in subtypes of epithelial ovarian cancer stages in relation to ethnic and age difference</title>
			<description>Epithelial ovarian cancer is the fifth leading cause of cancer mortality among women in the United States. For this disease, differences in age-adjusted incidence and survival rates between African American and Caucasian women are substantial. The objective of this study was to examine mtDNA sequence variants in 118 frozen tissues of three subtypes of epithelial ovarian cancer (serous, n = 48 endometrioid, n = 47 and mucinous, n = 23) and matched paracancerous normal tissues (n = 18) in relation to racial/ethnic and age differences. Restriction fragment length polymorphism (RFLP) and polymerase chain reaction (PCR)-based sequencing were used to evaluate two regions of mtDNA spanning 5317 to 7608 and 8282 to 10110 bp and including ND subunits 2, 3, MT-COI, II, and III, ATPase 8, a part of ATPase 6, and tRNA genes in frozen ovarian tissues obtained from the southern regional Cooperative Human Tissue Network (CHTN) and University of Alabama-Birmingham (UAB) Ovarian Spore Center. Thirty-nine mtDNA variants were detected of which 28 were previously unreported. One somatic variant of C9500T was observed. A variant, C7028T in the MT-CO1 gene, had an ascending frequency from borderline (8%) to stages III/IV (75%) among the three ovarian cancer subtypes and stages. It was found in 86% (42/49) of African-American and 43% (37/87) of the Caucasian women. A variant, T8548G in the ATPase 6 gene was detected at a frequency of 72% (18/25) in ovarian serous subtype tissues in stages III/IV. Of the African American patients under age 40, 95% (20/21) harbored the T8548G variant; this was in contrast to only 22% (8/35) of Caucasian patients in same age group. Variants C7256T and G7520A had a frequency of 54% (6/11) in endometrioid stage III; no corresponding variants were observed in mucinous subtype stage III. Furthermore, variants C7256T and G7520A were absent in serous ovarian cancer subtype. Interestingly, the C7520T variant in tRNA gene was present in 74% (36/49) of African American and 26% (23/87) of Caucasian patients. Taken together, our results suggest that, with respect to ethnic and age difference, these mtDNA variants may be involved in epithelial ovarian carcinogenesis.</description>
			<link>http://www.diagnosticpathology.org/content/3/1/32</link>
			
			 	<dc:creator>Felix O Aikhionbare, Sharifeh Mehrabi, Winston Thompson, Xuebiao Yao, William Grizzle and Edward Partridge</dc:creator>
			
			<dc:source>Diagnostic Pathology 2008, 3:32</dc:source>
			<dc:date>2008-07-28</dc:date>
			<dc:identifier>doi:10.1186/1746-1596-3-32</dc:identifier>
			
			
							
					<prism:publicationName>Diagnostic Pathology</prism:publicationName>
					
			
							
					<prism:issn>1746-1596</prism:issn>
					
			
							
					<prism:volume>3</prism:volume>
					
			
							
					<prism:startingPage>32</prism:startingPage>
					
			
							
					<prism:publicationDate>2008-07-28</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://www.diagnosticpathology.org/content/3/1/31">
            
            <title>Histological variants of cutaneous Kaposi sarcoma</title>
			<description>This review provides a comprehensive overview of the broad clinicopathologic spectrum of cutaneous Kaposi sarcoma (KS) lesions. Variants discussed include: usual KS lesions associated with disease progression (i.e. patch, plaque and nodular stage); morphologic subtypes alluded to in the older literature such as anaplastic and telangiectatic KS, as well as several lymphedematous variants; and numerous recently described variants including hyperkeratotic, keloidal, micronodular, pyogenic granuloma-like, ecchymotic, and intravascular KS. Involuting lesions as a result of treatment related regression are also presented.</description>
			<link>http://www.diagnosticpathology.org/content/3/1/31</link>
			
			 	<dc:creator>Liron Pantanowitz and Wayne Grayson</dc:creator>
			
			<dc:source>Diagnostic Pathology 2008, 3:31</dc:source>
			<dc:date>2008-07-25</dc:date>
			<dc:identifier>doi:10.1186/1746-1596-3-31</dc:identifier>
			
			
							
					<prism:publicationName>Diagnostic Pathology</prism:publicationName>
					
			
							
					<prism:issn>1746-1596</prism:issn>
					
			
							
					<prism:volume>3</prism:volume>
					
			
							
					<prism:startingPage>31</prism:startingPage>
					
			
							
					<prism:publicationDate>2008-07-25</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://www.diagnosticpathology.org/content/3/1/30">
            
            <title>How do surgical pathologists evaluate critical diagnoses (critical values)?</title>
			<description>Background:
After introduction of the concept of critical value (CV) in laboratory medicine, some efforts were performed to define possible critical values in surgical pathology. Critical diagnosis (critical value) is a concept recently established in surgical pathology and is a challenging issue among pathologists and clinical specialists. The concept may be the subject of variation according to the geographical or work setting differences. The current study was performed to bring the contribution of the Iranian pathologists to the evolving concept of critical diagnoses (critical values) in surgical pathology.Materials and methodsDuring annual meeting of Iranian Pathologist Society, November 2006, Tehran, Iran, anonymous questionnaires were distributed among participants. They were requested to openly name conditions in which a pathologist should communicate the results immediately with clinicians.
Results:
147 pathologists completed the questionnaire. They were varied in their level of experience and setting of workplace. Each participant referred to 1&#8211;7 (mean 3) conditions as CV. About 90 different conditions which were considered as CV by participants were extracted from the questionnaires.DiscussionThe list of conditions obtained through this survey as CVs in surgical pathology covered most items previously described in literature. Major differences are low number (or lack) of refers to some relatively routine and potentially important conditions and considering many unimportant conditions as CV by participants of present survey. Almost all conducted surveys have been performed on this issue so far (including the present survey) suffer from lack of supportive scientific evidences and based mainly on experience and common sense of participants in survey. Potential problems with application of CV concept in daily routine work flow of pathology, particularly in developing countries like Iran, were discussed.</description>
			<link>http://www.diagnosticpathology.org/content/3/1/30</link>
			
			 	<dc:creator>Masoud Mireskandari</dc:creator>
			
			<dc:source>Diagnostic Pathology 2008, 3:30</dc:source>
			<dc:date>2008-07-12</dc:date>
			<dc:identifier>doi:10.1186/1746-1596-3-30</dc:identifier>
			
			
							
					<prism:publicationName>Diagnostic Pathology</prism:publicationName>
					
			
							
					<prism:issn>1746-1596</prism:issn>
					
			
							
					<prism:volume>3</prism:volume>
					
			
							
					<prism:startingPage>30</prism:startingPage>
					
			
							
					<prism:publicationDate>2008-07-12</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://www.diagnosticpathology.org/content/3/1/29">
            
            <title>Expression of CD56 isoforms in primary and relapsed adult granulosa cell tumors of the ovary</title>
			<description>Background:
Adult granulosa cell tumors of the ovary (GCTs) are sex cord stromal tumors of unpredictable behaviour. Up to now, the prediction of the relapsing/malignant potential remains difficult. CD56 (NCAM) in GCTs was previously described in only two studies. However, the expression of its isoforms was not examined.
Methods:
30 GCTs (16 primaries, 14 relapses) were investigated immunohistochemically with antibodies against Pan-CD56 (CD56Pan) and the isoform with 140/180 kDa length (CD56140/180 kDa). The reaction was assessed with respect to percentage of positive cells and intensity of staining.
Results:
In all GCTs, CD56Pan was expressed, but differences were found between primaries and relapses. The percentage of CD56Pan positive tumor cells was lower in relapses, whereas CD56140/180 kDa showed a higher staining intensity in the latter.
Conclusion:
Expression of CD56 is an additional sensitive and helpful immunohistochemical tool for histopathologists diagnosing a GCT. It does not seem possible to provide a validly individual risk assessement. However, the different expression of CD56 isoforms might indicate important changes in the course to a more malignant behaviour.</description>
			<link>http://www.diagnosticpathology.org/content/3/1/29</link>
			
			 	<dc:creator>Hans-Ullrich V&#246;lker, Sabine Engert, Andreas Cramer, Melanie Schmidt, Ulrike K&#228;mmerer, Hans-Konrad M&#252;ller-Hermelink and Stefan Gattenl&#246;hner</dc:creator>
			
			<dc:source>Diagnostic Pathology 2008, 3:29</dc:source>
			<dc:date>2008-07-09</dc:date>
			<dc:identifier>doi:10.1186/1746-1596-3-29</dc:identifier>
			
			
							
					<prism:publicationName>Diagnostic Pathology</prism:publicationName>
					
			
							
					<prism:issn>1746-1596</prism:issn>
					
			
							
					<prism:volume>3</prism:volume>
					
			
							
					<prism:startingPage>29</prism:startingPage>
					
			
							
					<prism:publicationDate>2008-07-09</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://www.diagnosticpathology.org/content/3/1/28">
            
            <title>Does the radiofrequency impedance-controlled endometrial ablation have any morphologic effects on uterine leiomyomata?: Report of 3 cases</title>
			<description>A variety of novel endometrial ablation technologies are now in routine use. A subset of uteri that had previously undergone these treatments will ultimately be evaluated by the pathologist. However, the full spectrum of histologic changes that may result from these treatments has received only sporadic attention. The NovaSure&#8482; [Hologic Corporation, Marlborough, MA, USA] endometrial ablation system is one of several available second-generation technologies and its particular endometrial ablative power is based on the delivery of radiofrequency energy. The present analysis was designed to decipher any histologic changes (if any) associated with the NovaSure&#8482; endometrial ablation system relative to benign smooth muscle tumors of the uterine corpus. Over a one-year period, 3 uteri that had previously undergone the NovaSure&#8482; endometrial ablation and which also had leiomyomatous mass lesions were evaluated. The leiomyomatous mass lesions were extensively sampled and were evaluated for cellular shapes (epithelioid change, cellular rounding, extraordinary cytoplasmic eosinophilia, clear cell change, cytoplasmic vacuolation), nuclear changes (nucleomegaly, nucleolomegaly, multinucleation, hyperchromasia, symplastic changes), necrosis (coagulative and/or infarct), mitotic activity, apoptotic bodies or pyknotic cells, myxoid change, hyalinization. The three uteri were resected 61, 47 and 74 (mean 60.7) days post-ablation. After a detailed evaluation of multiple submucosal, intramural and subserosal leiomyomata from these 3 uteri, no noteworthy histologic changes were identified in the tumors. Since the presence or absence of tumor necrosis is one histologic criterion by which malignant potential is assigned to uterine smooth muscle neoplasms, defining any extrinsic processes that may establish, or contribute to this finding is clinically relevant. The findings reported herein suggests that if a leiomyoma that was obtained from a patient that had recently undergone the NovaSure&#8482; endometrial ablation displays any degenerative changes such as necrosis, the changes are probably not attributable to the ablation.</description>
			<link>http://www.diagnosticpathology.org/content/3/1/28</link>
			
			 	<dc:creator>Oluwole Fadare, Sa A Wang and Idris L Renshaw</dc:creator>
			
			<dc:source>Diagnostic Pathology 2008, 3:28</dc:source>
			<dc:date>2008-07-01</dc:date>
			<dc:identifier>doi:10.1186/1746-1596-3-28</dc:identifier>
			
			
							
					<prism:publicationName>Diagnostic Pathology</prism:publicationName>
					
			
							
					<prism:issn>1746-1596</prism:issn>
					
			
							
					<prism:volume>3</prism:volume>
					
			
							
					<prism:startingPage>28</prism:startingPage>
					
			
							
					<prism:publicationDate>2008-07-01</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://www.diagnosticpathology.org/content/3/1/27">
            
            <title>Sodium polystyrene sulfonate (Kayexalate) aspiration</title>
			<description>In this short report we illustrate a case of extensive sodium polystyrene sulfonate (SPS) aspiration as an immediate cause of death in a terminally ill patient. SPS is a cation exchange resin utilized to decrease potassium levels in patients with renal failure. When administered rectally in conjunction with sorbitol, colonic necrosis and perforation have been documented. On the other hand, oral administration can be complicated by aspiration, especially in very ill or debilitated patients. In our current report, histological examination of a patient who aspirated SPS shows multiple polygonal to amorphous basophilic crystalline particles deposited intraalveolarly. The purpose of our report is to familiarize pathologists with the histologic features of this rare iatrogenic complication of therapy for hyperkalemia.</description>
			<link>http://www.diagnosticpathology.org/content/3/1/27</link>
			
			 	<dc:creator>Luis F Gonzalez-Cuyar, Nathaniel B Cresswell and Allen P Burke</dc:creator>
			
			<dc:source>Diagnostic Pathology 2008, 3:27</dc:source>
			<dc:date>2008-06-17</dc:date>
			<dc:identifier>doi:10.1186/1746-1596-3-27</dc:identifier>
			
			
							
					<prism:publicationName>Diagnostic Pathology</prism:publicationName>
					
			
							
					<prism:issn>1746-1596</prism:issn>
					
			
							
					<prism:volume>3</prism:volume>
					
			
							
					<prism:startingPage>27</prism:startingPage>
					
			
							
					<prism:publicationDate>2008-06-17</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://www.diagnosticpathology.org/content/3/1/26">
            
            <title>Is collagenase-3 (MMP-13) expression in chondrosarcoma of the jaws a true marker for tumor aggressiveness?</title>
			<description>Background:
Matrix metalloproteinases (MMPs) play an important role in the modeling and remodeling of the extracellular matrix in both physiologic and pathologic states and thus plays an important role in tumor progression. Human collagenase-3 (MMP-13) is a member of matrix metalloproteinase family of enzymes that was originally identified in breast carcinomas and subsequently detected during fetal ossification and in arthritic processes.AimThe present study was designed to investigate the expression MMP-13 and to correlate its expression with clinicopathological parameters in chondrosarcoma of the jaws.
Methods:
Archival tumor tissues from 11 patients with chondrosarcoma of the jaws were analyzed by immunohistochemistry for the expression of MMP-13. Clinical information was obtained through the computerized retrospective database from the tumor registry between 1998 to 2006.
Results:
Eight of 11 cases (72.8 %) of chondrosarcomas showed a positive reaction for MMP-13, whereas two cases of normal cartilage were negative for this collagenase. As regard the clinicopathological parameters, there was no correlation between MMP-13 expression and sex, age and tumor site. While, there were significant associations between MMP-13 expression and both of mitotic counts and necrosis. On the other hand, there was a significant difference between low and high grade tumors (P &lt; 0.05) regarding MMP-13 expression. Also, there was no significant correlation between MMP-13 expression in primary lesions and their local recurrence.
Conclusion:
MMP-13 is expressed in the majority of chondrosarcoma of the jaws. It is also noteworthy that the expression of MMP-13 may be related to tumor biological aggressiveness and used to aid in predicting patient's poor prognosis.</description>
			<link>http://www.diagnosticpathology.org/content/3/1/26</link>
			
			 	<dc:creator>Manal M Zyada and Ali A Shamaa</dc:creator>
			
			<dc:source>Diagnostic Pathology 2008, 3:26</dc:source>
			<dc:date>2008-06-13</dc:date>
			<dc:identifier>doi:10.1186/1746-1596-3-26</dc:identifier>
			
			
							
					<prism:publicationName>Diagnostic Pathology</prism:publicationName>
					
			
							
					<prism:issn>1746-1596</prism:issn>
					
			
							
					<prism:volume>3</prism:volume>
					
			
							
					<prism:startingPage>26</prism:startingPage>
					
			
							
					<prism:publicationDate>2008-06-13</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
		
    <cc:License rdf:about="http://creativecommons.org/licenses/by/2.0/">
         <cc:permits rdf:resource="http://creativecommons.org/ns#Reproduction"/>
         <cc:permits rdf:resource="http://creativecommons.org/ns#Distribution"/>
         <cc:permits rdf:resource="http://creativecommons.org/ns#DerivativeWorks"/>
	</cc:License>
</rdf:RDF>
